

Cover Story
Relying largely on maturing data from the European trials of screening for prostate cancer, the U.S. Preventive Services Task Force has given a better grade—a “C”—to screening for prostate cancer.
By Matthew Bin Han Ong
In Brief
Funding Opportunities
Clinical Roundup
Drugs & Targets
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - California’s Prop 38 is an historic approach to funding medical research, immunology
The $8.4B bond makes a long-term investment in a field with life-saving power - Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - NCI’s new CCSG is the result of “thousands of hours” of listening, negotiations, surprises
New NOFO aims to shrink applications by 40% - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Kevan Shokat made KRAS druggable. With daraxonrasib now in the clinic, he is “all in” on the ultimate target: p53
Shokat was named 2026 Stephenson Global Prize winner




















